deferoxamine has been researched along with Endocrine System Diseases in 18 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Endocrine System Diseases: Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In 18 requiring thyroxine supplementation for hypothyroidism, 10 were able to discontinue, and four reduced their thyroxine dose." | 5.14 | Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. ( Berdoukas, V; Chouliaras, G; Farmaki, K; Pappa, C; Tzoumari, I, 2010) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "Diabetes mellitus was present in 6." | 2.61 | Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis. ( Chen, DY; Chen, W; He, LN; Liu, NQ; Lu, D; Sun, XF; Xie, YJ; Xiong, ZY; Yang, Y; Yang, YH, 2019) |
| "Treatment of patients with beta-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized." | 1.32 | Complications of beta-thalassemia major in North America. ( Cohen, AR; Cunningham, MJ; Macklin, EA; Neufeld, EJ, 2004) |
| "To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient's physical and social well-being." | 1.31 | Impact of thalassemia major on patients and their families. ( Arana, A; Caro, JJ; Eleftheriou, A; Green, TC; Huybrechts, K; Wait, S; Ward, A, 2002) |
| "Juvenile haemochromatosis is a rare inborn error of iron metabolism with clinical manifestations before 30 years of age." | 1.30 | Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease. ( Cox, TM; Kelly, AL; Rhodes, DA; Roland, JM; Schofield, P, 1998) |
| "Three patients had evidence of primary hypothyroidism." | 1.29 | Multiple hormone deficiencies in children with hemochromatosis. ( Cassorla, FG; Kamp, GA; Manasco, PK; Munson, PJ; Nienhuis, AW; Oerter, KE, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (22.22) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, LN | 1 |
| Chen, W | 1 |
| Yang, Y | 1 |
| Xie, YJ | 1 |
| Xiong, ZY | 1 |
| Chen, DY | 1 |
| Lu, D | 1 |
| Liu, NQ | 1 |
| Yang, YH | 1 |
| Sun, XF | 1 |
| Farmaki, K | 1 |
| Tzoumari, I | 1 |
| Pappa, C | 1 |
| Chouliaras, G | 1 |
| Berdoukas, V | 1 |
| Belhoul, KM | 1 |
| Bakir, ML | 1 |
| Saned, MS | 1 |
| Kadhim, AM | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Davis, BA | 1 |
| Porter, JB | 1 |
| Cunningham, MJ | 1 |
| Macklin, EA | 1 |
| Neufeld, EJ | 1 |
| Cohen, AR | 1 |
| Vogiatzi, MG | 1 |
| Autio, KA | 1 |
| Mait, JE | 1 |
| Schneider, R | 1 |
| Lesser, M | 1 |
| Giardina, PJ | 1 |
| Wang, CH | 1 |
| Wu, KH | 1 |
| Tsai, FJ | 1 |
| Peng, CT | 1 |
| Tsai, CH | 1 |
| Gabutti, V | 1 |
| Borgna-Pignatti, C | 2 |
| Zurlo, MG | 1 |
| DeStefano, P | 1 |
| Boffa, C | 1 |
| DeSanctis, V | 1 |
| DiPalma, A | 1 |
| DiGregorio, L | 1 |
| Melevendi, C | 1 |
| Piga, A | 1 |
| Sabato, V | 1 |
| Oerter, KE | 1 |
| Kamp, GA | 1 |
| Munson, PJ | 1 |
| Nienhuis, AW | 1 |
| Cassorla, FG | 1 |
| Manasco, PK | 1 |
| Jensen, CE | 1 |
| Tuck, SM | 1 |
| Old, J | 1 |
| Morris, RW | 1 |
| Yardumian, A | 1 |
| De Sanctis, V | 1 |
| Hoffbrand, AV | 1 |
| Wonke, B | 1 |
| Kelly, AL | 1 |
| Rhodes, DA | 1 |
| Roland, JM | 1 |
| Schofield, P | 1 |
| Cox, TM | 1 |
| Prati, D | 1 |
| Caro, JJ | 1 |
| Ward, A | 1 |
| Green, TC | 1 |
| Huybrechts, K | 1 |
| Arana, A | 1 |
| Wait, S | 1 |
| Eleftheriou, A | 1 |
| Cividalli, G | 1 |
| O'Brien, RT | 2 |
| Pearson, HA | 1 |
| Festa, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thalassemia Clinical Research Network (TCRN)[NCT00000623] | 1,000 participants (Anticipated) | Observational | 2000-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for deferoxamine and Endocrine System Diseases
| Article | Year |
|---|---|
Elevated Prevalence of Abnormal Glucose Metabolism and Other Endocrine Disorders in Patients with β-Thalassemia Major: A Meta-Analysis.
Topics: beta-Thalassemia; Chelation Therapy; Deferoxamine; Diabetes Mellitus; Endocrine System Diseases; Glu | 2019 |
Results of long term iron chelation treatment with deferoxamine.
Topics: Deferoxamine; Ear, Inner; Endocrine System Diseases; Eye; Heart Diseases; History, 20th Century; Hum | 2002 |
Clinical manifestations and therapy of transfusional haemosiderosis.
Topics: Adolescent; Adult; Chelation Therapy; Deferoxamine; Endocrine System Diseases; Female; Heart Disease | 1994 |
Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major.
Topics: Anemia, Hemolytic; beta-Thalassemia; Blood Group Incompatibility; Blood Transfusion; Cardiovascular | 2000 |
Iron overload: clinical and pathologic aspects in pediatrics.
Topics: Abnormalities, Multiple; Adolescent; Adult; Ascorbic Acid Deficiency; Bloodletting; Child; Child, Pr | 1977 |
Modern management of thalassemia.
Topics: Adolescent; Arrhythmias, Cardiac; Ascorbic Acid; Blood Transfusion; Child; Cholelithiasis; Deferoxam | 1985 |
2 trials available for deferoxamine and Endocrine System Diseases
| Article | Year |
|---|---|
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Cardiomyopathies; Child; Deferiprone; Deferoxami | 2010 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
10 other studies available for deferoxamine and Endocrine System Diseases
| Article | Year |
|---|---|
Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Child; Cross-Sectional Studies; Deferoxamine | 2012 |
Complications of beta-thalassemia major in North America.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; | 2004 |
Low bone mineral density in adolescents with beta-thalassemia.
Topics: Adolescent; Adult; Anthropometry; beta-Thalassemia; Blood Transfusion; Bone Density; Bone Diseases, | 2005 |
Outcome of thalassemia treated with conventional therapy.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Cardiovascular Diseases; Cause of Death; Chelation | 1993 |
Multiple hormone deficiencies in children with hemochromatosis.
Topics: Adolescent; Child; Deferoxamine; Endocrine System Diseases; Female; Follicle Stimulating Hormone; Go | 1993 |
Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferoxamine; Endocrine System Diseases; Female; Genotyp | 1997 |
Hereditary juvenile haemochromatosis: a genetically heterogeneous life-threatening iron-storage disease.
Topics: Adolescent; Adult; Age of Onset; Chelating Agents; Deferoxamine; Endocrine System Diseases; Female; | 1998 |
Impact of thalassemia major on patients and their families.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Cost of Illness; Deferoxamine; Diabetes Complications; E | 2002 |
The clinical management of homozygous beta-thalassemia.
Topics: Blood Transfusion; Deferoxamine; Endocrine System Diseases; Growth Disorders; Humans; Splenectomy; T | 1979 |
The management of thalassemia major.
Topics: Adolescent; Adult; Blood Transfusion; Chelating Agents; Child; Child, Preschool; Deferoxamine; Diet | 1975 |